Precipio Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 160/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Precipio Inc's Score
Industry at a Glance
Industry Ranking
160 / 208
Overall Ranking
475 / 4582
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Precipio Inc Highlights
StrengthsRisks
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 96.90% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.53M.
Undervalued
The company’s latest PE is -27.55, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 199.00K shares, increasing 11.63% quarter-over-quarter.
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Ticker SymbolPRPO
CompanyPrecipio Inc
CEODanieli (Ilan S)
Websitehttps://www.precipiodx.com/
FAQs
What is the current price of Precipio Inc (PRPO)?
The current price of Precipio Inc (PRPO) is 22.190.
What is the symbol of Precipio Inc?
The ticker symbol of Precipio Inc is PRPO.
What is the 52-week high of Precipio Inc?
The 52-week high of Precipio Inc is 28.500.
What is the 52-week low of Precipio Inc?
The 52-week low of Precipio Inc is 3.900.
What is the market capitalization of Precipio Inc?
The market capitalization of Precipio Inc is 38.74M.
What is the net income of Precipio Inc?
The net income of Precipio Inc is -4.29M.
Is Precipio Inc (PRPO) currently rated as Buy, Hold, or Sell?
According to analysts, Precipio Inc (PRPO) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Precipio Inc (PRPO)?
The Earnings Per Share (EPS TTM) of Precipio Inc (PRPO) is -0.806.